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Hepatocyte growth factor (HGF) is an angiogenic, cardioprotective factor important for tissue and
vascular repair. High levels of HGF are associated with chronic inﬂammatory diseases, such as coronary
artery disease (CAD) and periodontitis, and are suggested as a marker of the ongoing atherosclerotic
event in patients with CAD. Periodontal disease is more prevalent among patients with CAD than
among healthy people. Recent studies indicate a reduced biological activity of HGF in different chronic
inﬂammatory conditions. Biologically active HGF has high afﬁnity to heparan sulfate proteoglycan
(HSPG) on cell-membrane and extracellular matrix. The aim of the study was to investigate the serum
concentration and the biological activity of HGF with ELISA and surface plasmon resonance (SPR),
respectively, before and at various time points after percutaneous coronary intervention (PCI) in
patients with CAD, and to examine the relationship with periodontal condition. The periodontal status
of the CAD patients was examined, and the presence of P. gingivalis in periodontal pockets was analyzed
with PCR. The HGF concentration was signiﬁcantly higher, at all time-points, in patients with CAD
compared to the age-matched controls (Po 0.001), but was independent of periodontal status. The HGF
concentration and the afﬁnity to HSPG adversely ﬂuctuated over time, and the biological activity
increased one month after intervention in patients without periodontitis. We conclude that elevated
concentration of HGF but with reduced biological activity might indicate a chronic inﬂammatory proﬁle
in patients with CAD and periodontitis.
& 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
Hepatocyte growth factor (HGF), an angiogenic and regenera-
tive factor with cytoprotective effects, has gained substantial
attention for its cardioprotective involvement in coronary ische-
mia and infarction [1–4]. The HGF receptor, the proto-oncogene
c-Met, is a transmembrane tyrosine kinase receptor expressed byr, University Hospital,
ax: þ46 19 602 6650.
Y-NC-ND license.almost all epithelial, endothelial, and erythroid progenitor
cells [5]. In addition, a low-afﬁnity binding site has been identi-
ﬁed on heparan sulfate proteoglycan (HSPG) [6], a sulfated
glycoprotein present on the cell surface in essentially all tissues
and in the extracellular matrix [7]. HSPG binds and facilitates the
cytokine–receptor interaction [8–10] as well as the conversion of
promitogen HGF to the two-chain active form [6,11].
A number of studies have demonstrated elevated HGF levels in
patients with various chronic diseases [12,13]; however, despite
high concentrations, HGF may appear in a form with reduced
biological activity [14]. Furthermore, administration of exogenous
HGF is shown to prevent tissue ﬁbrosis and dysfunction in chronic
J. Lo¨nn et al. / Results in Immunology 2 (2012) 7–128disease models [15–17]. High levels of HGF are also associated
with coronary artery disease (CAD) [18,19], and it has been
suggested that circulating levels of HGF may provide a useful
marker of atherothrombosis in patients with established CAD,
reﬂecting the extent or activity of atherosclerosis. In addition,
HGF and c-Met are expressed in the atherosclerotic vessel wall
and in plaque [4,20].
There is an emerging interest in the link between oral health
and systemic diseases, such as CAD. Indeed, periodontal disease is
more prevalent among patients with CAD than among healthy
people [21,22]. Porphyromonas gingivalis (P. gingivalis) is an
etiological agent strongly associated with periodontal disease
[23] and correlates with numerous inﬂammatory disorders, such
as cardiovascular and rheumatic disease. P. gingivalis has been
detected in human atheromatous carotid plaques [24], and serum
antibodies to P. gingivalis have been shown to predict myocardial
infarction [25]. Furthermore, periodontal pockets with a high
number of periodontally pathogenic bacteria are a risk factor for
acute coronary syndrome [26]. Chronically inﬂamed periodontal
pockets may serve as a reservoir for inﬂammatory stimuli, and by
entering the circulation, oral bacteria and their components
activate neutrophils and platelets, thereby inducing production
of reactive oxygen species [27], and triggering the inﬂammatory
process in the carotid vessels. P. gingivalis contributes to period-
ontal disease via virulence factors such as cysteine proteinases
(gingipains), ﬁmbriae, and LPS, and an infection may lead to
chronic inﬂammation in which hyper-responsive neutrophils
contribute to host-mediated tissue destruction. In periodontitis,
HGF concentrations, in gingival crevicular ﬂuid and in saliva,
increase proportionally with the progression of periodontal dis-
ease [28], and P. gingivalis stimulates HGF synthesis in human
gingival ﬁbroblasts [29].
While ELISA is a reliable, sensitive method for protein detec-
tion, this method does not differentiate between biologically
active and inactive HGF [14]. The binding of HGF to HSPG has
previously been shown to be important for the biological activityTable 1
Baseline data. Serum hepatocyte growth factor (HGF) concentration (ng/mL) and bindin
with coronary artery disease (CAD) and in healthy controls. The patients are clas
periodontitis) and negative or positive for Porphyromonas gingivalis (P. gingivalis) in per
statistically signiﬁcant.
Patients
Gingivitis Moderate periodontitis
P. gingivalis P. gingivalis
Neg Pos Neg Pos
Age (mean 7SD)
Subgroups 57.075.0 59.078.6 57.878.4 64.076
Groups 57.876.7 60.578.5
Total 59.977.4
Sex (M/F (total))
Subgroups 8/0 (8) 3/1 (4) 5/4 (9) 1/4 (5)
Groups 11/1 (12) 6/8 (14)
Total 26/10 (36)
HGF baseline (mean 7SD)
Subgroups 1.1470.47 1.1770.24 1.1270.79 1.1070
Groups 1.1570.40 1.1170.44
Total 1.1170.37
HSPG baseline (mean 7SD)
Subgroups 16.2721.1 11.0714.9 14.8713.3 8.276.
Groups 15.0719.0 12.4712.3
Total 13.0714.6
a Fisher’s exact test for sex and Mann–Whitney’s U-test and Kruskal–Wallis ANOV
b Differences between positive and negative P. gingivalis (Mann–Whitney’s U-test).of HGF and for the induction of cellular responses [30,31]. Surface
plasmon resonance (SPR) is an optical technique that can deter-
mine the afﬁnity of a protein for several ligands or epitopes
[32,33]. SPR-based assessment of the binding proﬁle of HGF to
HSPG may rapidly and sensitively distinguish HGF variants with
different biological activities. Appropriate for clinical studies, this
method can be used for evaluation of the quality of endogenous
HGF [30].
The aim of the present study was to investigate the concen-
tration and the biological activity of HGF with ELISA and SPR,
respectively, in patients with conﬁrmed CAD, and to examine
the relationship with periodontal disease and the presence of
P. gingivalis in periodontal pockets.2. Material and methods
2.1. Study subjects and protocol
Thirty six (mean age 59.9 years; range 41–73 years; 26 men
and 10 women) out of a total of 90 patients who underwent
coronary angiography between February 2003 and 2007 due to
chest pain were randomly selected and enrolled in this study
(Table 1). Exclusion was based on the following criteria: age
above 75 years, ongoing cortisone medication, ongoing treated
infection, or malignity. Peripheral venous blood was drawn into
heparin-containing (20 U/mL) vacutainer tubes from the patients
before, as well as 24 h, 1 month, 6 and 12 months after
angiography and percutaneous intervention (PCI). The blood
samples were centrifuged at 3000g for 10 min; the serum was
collected and frozen at 70 1C within 45 min of collection. All
patients were treated with acetyl salicylic acid (75 mg) once daily
before and after the procedures, and they were also given a
loading dose of 300 mg clopidogrel approximately 12 h prior to
PCI. Patients with unstable angina (n¼4) were given acetylsa-
licylic acid, clopidogrel, and low molecular heparin until the timeg afﬁnity to heparan sulfate proteoglycan (HSPG) (response units; RU) in patients
siﬁed into periodontal conditions (gingivitis, moderate periodontitis, or severe
iodontal pockets. The data are presented as mean7SD, and Po0.05 is considered
Controls
Severe periodontitis
P. gingivalis
Neg Pos p-Valuesa
.5 62.876.3 60.776.9 – 0.240b
61.776.8 – 0.475
59.377.3 0.608
4/1 (5) 5/0 (5) – –
9/1 (10) – –
41/15 (56) 01.00
.47 1.1470.40 1.0670.16 – 0.881b
1.0770.17 – 0.270
0.7870.29 o0.001
8 14.2715.7 9.874.9 – 0.702b
11.3712.4 – 0.sta
14.5715.8 0.400
A by ranks for continuous variables.
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after the PCI.
A control group matched for age and gender comprised of 56
subjects randomly drawn from eligible participants in the popu-
lation based on ‘‘Life Conditions, Stress and Health-study’’ [34].
Participants with reported coronary heart disease or angina
pectoriswere excluded prior to matching. Peripheral venous blood
was drawn at one occasion and handled in the same way as
described earlier.
The study protocol was approved by the Regional Ethical
Review Board in Linko¨ping, Sweden, and all participants provided
written, informed consent.
2.2. Periodontal examination
Three months after each subject had undergone intervention,
a dental examination was performed. Anamnesis, clinical period-
ontal examination, and a panoramic radiograph were recorded for
each subject. Periodontal conditions were scored according to
Lindhe and Nyman [35]. The number of remaining teeth (exclud-
ing third molars) was recorded, and plaque scores (PlI%) were
calculated based on the presence or absence of visible plaque at
the gingival margin on four surfaces (buccal, lingual, mesial, and
distal) of each tooth. Periodontal pockets were recorded on each
tooth surface with a depth exceeding 4 mm using a manual
periodontal probe (HuFriedy PCP 11). Based on clinical and
radiographic ﬁndings, all subjects were classiﬁed into one of the
three groups according to the severity of periodontal disease,
criteria modiﬁed from Hugoson and Jordan [36]: gingivitis: normal
alveolar bone height, and 412 bleeding gingival units in the
molar–premolar regions; moderate periodontitis: alveolar bone
loss around the majority of the teeth not exceeding 1/3 of normal
bone height; severe periodontitis: alveolar bone loss around the
majority of the teeth exceeding 1/3 of normal bone height and
presence of angular bony defects and/or furcation defects.
In patients with preserved teeth, subgingival microbial sam-
ples were collected from the four deepest periodontal pockets in
the mouth. Supragingival plaque was removed, the root surface
was dried, and a sterile endodontic paper point was inserted into
the bottom of the pocket for 20 s. The pooled samples from each
patient were stored in a sterile tube and transported to the
laboratory for analysis of the prevalence of P. gingivalis.
2.3. PCR detection of P. gingivalis
The presence of P. gingivalis in the subgingival samples was
analyzed by PCR [37]. Brieﬂy, DNA was isolated using the Jetquick
tissue DNA spin kit (Genomed, Lo¨hne, Germany) according to the
manufacturer’s instructions. Five microliters of the extracted tem-
plate was added to puRe Taq Ready-To-Go PCR Beads (Amersham
Biosciences, Uppsala, Sweden) containing 200 mM of each dNTP,
2.5 U puReTaq DNA polymerase, 10 mM Tris–HCl [pH 9.0 at room
temperature], 50 mM KCl, and 1.5 mM MgCl2 together with 0.4 mM
of each primer (upstream primer: 50-AGG CAG CTT GCC ATA CTG
CG-30 and downstream primer: 50-ATC GTT AGC AAC TAC CAG TGT-
30; MWG Biotech AG, Ebersberg, Germany). P. gingivalis DNA (ATCC
33277D) was used as positive control. The template was ampliﬁed
(Mastercyclers: Eppendorf, Hamburg, Germany) with an initial
denaturation step at 95 1C for 10 min, followed by 36 cycles of
denaturation at 95 1C for 30 s, annealing at 60 1C for one minute,
and extension at 72 1C for one minute. The ampliﬁed product was
stored at 4 1C for at most one hour before being separated by gel
electrophoresis in 1.2% E-Gels Agarose Gels (Invitrogen, Carlsbad,
CA, USA) containing ethidium bromide, together with the Jetway
1000/100 bp ladder (Genomed, Lo¨hne, Germany). The ampliﬁed
product of 404 bp was visualized by UV light.2.4. ELISA measurement of serum HGF concentration
The HGF concentration in serum collected before and at 24 h,
1 month, 6 months, and 12 months after coronary angiography
with PCI was determined using an ELISA kit (Quantikine Human
HGF immunoassay, minimum detectable limit: 0.04 ng/mL; R&D
Systems, Minneapolis, MN, USA) according to the manufacturer’s
instructions. The measurements of the samples from the different
groups and time points were performed in duplicate at 450 nm
using an ELISA reader (Expert 96; Asys Hitech GmbH, Eugendorf,
Austria), and calibrated using the recombinant human HGF refer-
ence samples and standards that were provided in the ELISA kit.
2.5. Serum HGF activity
The biological activity of HGF was analyzed by Surface Plasmon
Resonance (SPR) measuring binding afﬁnity to HSPG (Sigma-
Aldrich, St. Louis, MO, USA) as previously described [30]. Brieﬂy,
SPR measurements and ligand immobilization procedures were
conducted at 760 nm in a fully automatic Biacore 2000 instrument
(GE-Healthcare GmbH, Uppsala, Sweden) equipped with four ﬂow
cells; the ﬂow cell temperature was 25 1C in all experiments.
HBS-EP buffer (0.01 M HEPES [pH 7.4], 0.15 M NaCl, 3 mM EDTA,
0.005% surfactant P20) (GE-Healthcare GmbH) was used as a
running buffer. The ligand (HSPG) was coupled to carboxymethy-
lated dextran CM5 chips (GE Healthcare GmbH) by conventional
carbodiimide chemistry using 200 mM N-ethyl-N0-(3-diethylami-
nopropyl) carbodiimide and 50 mM N-hydroxysuccinimide. The
activation time was 7 min, followed by a 7 min ligand injection.
Deactivation of the remaining active esters was performed by a
7 min injection of ethanolamine/hydrochloride [pH 8.5]. A ﬂow
rate of 5 mL/min was used during immobilization and measure-
ment procedures. HSPG (Z400 mg/mL protein and 400 mg/mL
glycosaminoglycan) was diluted in a ratio of 1:10 in 10 mM
acetate buffer [pH 4.5] below the isoelectric point of the protein,
thus enhancing the electrostatic interactions between the dextran
matrix and the ligand. The contact time was 7 min, which resulted
in immobilization levels around 15,000 response units (RU).
Serum samples were diluted in a ratio of 1:20 in PBS [pH 7.4]
(Apoteket AB, Umea˚, Sweden). An equal mixture of 1 M NaCl and
10 mM glycine [pH 2] followed by one injection of borate [pH 8.5]
was used as a regeneration buffer. A positive and a negative
control were included at the beginning and at the end of each run
to conﬁrm the reliability of the surfaces.
2.6. Statistical analysis
The data were normally distributed after logarithmation and
analyzed by repeated measures of ANOVA followed by Neuman–
Keuls Post Hoc test, using Statistica Software and/or Graph Pad
Prism. P-values below 0.05 were considered statistically signiﬁ-
cant and results are expressed as mean7SD.3. Results
The periodontal status was distributed as following: gingivitis
n¼12, moderate periodontitis n¼14, severe periodontitis n¼10.
14 (39%) of the patients were positive for P. gingivalis and 22 (61%)
negative (Table 1). Periodontal conditions are shown in Table 2.
Prior to the PCI intervention, the mean HGF concentration in
the patient group was signiﬁcantly higher (Po0.001) than in the
age-matched healthy control group, and the HGF concentration
did not signiﬁcantly differ between sampling times (Table 1).
Additionally, there were no differences in HGF levels between
the groups with different periodontal status (Fig. 1A), neither
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ontal pockets (Fig. 1C) (Table 1).
The HGF serum concentration ﬂuctuated adversely to the
binding afﬁnity to HSPG (which indicates the biological activity
of HGF); the mean HGF concentration increased 24 h after the PCI
intervention in patients without periodontitis (patients withTable 2
Periodontal conditions of the patients with CAD. Periodontal parameters in the
group of 36 heart patients with PCI; mean number of remaining teeth, % of
surfaces with visible plaque at the gingival margin (PI), % of surfaces with bleeding
at the gingival margin (GI), % of surfaces with bleeding on probing (BOP), number
of probing pocket depths (PPD).
Variable Mean SD Range (Max–Min)
Number of teeth 24.6 2.0 7 (28–21)
Plaque (%) 44.2 17.8 44 (66–22)
GI (%) 45.4 21.0 58 (69–11)
BOP (%) 14.8 14.0 43 (43–0)
4–6 mm PPD 14.0 12.3 39 (401)
46 mm PPD 1.56 3.25 9 (9–0)
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Fig. 1. Serum concentration and biological activity of hepatocyte growth factor in pat
sulfate proteoglycan; HSPG) of hepatocyte growth factor (HGF) in serum taken before (p
intervention (PCI) from patients with coronary artery disease (CAD) and with gingivitis
into negative or positive for Porphyromonas gingivalis (P. gingivalis) in dental pockets (
binding afﬁnity to HSPG was measured with surface plasmon resonance (SPR) and data a
for statistical analysis and data are presented as mean7SD. nPo0.05.gingivitis), while the binding afﬁnity to HSPG at the same time
decreased. After one month the HGF concentration showed the
lowest level, while the afﬁnity to HSPG reached the highest peak
at the same time (Po0.05; binding afﬁnity to HSPG 24 h vs. one
month in patients with gingivitis) (Fig. 1).4. Discussion
As observed in previous studies of chronic inﬂammatory
diseases [13], we demonstrate in this study signiﬁcantly higher
serum concentration of HGF in patients with CAD, compared to an
age/sex-matched control group. However, the binding afﬁnity to
HSPG, reﬂecting the biological activity of HGF, increased in the
patients with CAD without periodontitis (but with gingivitis), one
month after PCI, but decreased to the same level as prior to
intervention after 12 months. Thus, the HGF serum concentration
ﬂuctuated adversely to the biological activity of HGF, i.e. when the
concentration of HGF increased the biological activity of HGF
decreased and vice versa. This phenomenon indicates that in
chronic inﬂammatory conditions the binding afﬁnity to HSPG is
decreased, possibly through proteolytic cleavage and thereby0.4
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ients with CAD. The concentration and the biological activity (binding to heparan
re), 24 h, 1 month, 6 and 12 months after angiography and percutaneous coronary
, moderate periodontitis, or severe periodontitis (A, B). Patients were also grouped
C, D). The concentration of HGF (ng/mL) was measured with ELISA (A, C), and the
re expressed as response units (RU) (B, D). Repeated measures of ANOVA was used
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receptor [8–10,38,39], causing additional elevated circulatory
levels of HGF [40]. According to these data, the PCI in the CAD
patients in our study may temporarily open the occluded vessel
and improve the blood ﬂow, but have no effects on the inﬂam-
matory process of atherosclerosis in the vessel wall. These
observations support the role of chronic inﬂammation in the
pathophysiology of CAD, and may have an impact on future
strategies in diagnosis, evaluation, and treatment of CAD.
Indeed, several previous studies strengthen the notion of the
importance of endogenous biologically active HGF in the regen-
eration, and healing of injuries, during chronic inﬂammatory
diseases, such as in the cardiovascular system [9,19,41,42], where
endogenous HGF may be present in a reduced biological active
form. The HGF concentration, which is elevated during chronic
inﬂammation, has been used as a marker of the chronic status and
as a monitor to predict the response to therapy [28]. In previous
studies, we used an in vitro SPR system to analyze the binding
afﬁnity to HSPG, in comparison to the motogenic activity of HGF
measured in a model of cell injury, to establish a method for
evaluation of the biological activity of HGF [30]. We found that
the biological activity of HGF was decreased in ulcer secretion
from patients with chronic ulcers, who responded well to admin-
istration of biologically active HGF [19]. Whether HGF is a potent
therapeutic tool for the treatment of chronic damage induced by
untreated chronic infections requires further investigations.
The present study has limitations that should be considered in
future prospective investigations. The study material includes not
more than 36 patients that were sub grouped in either three
periodontal status, or in P. gingivalis positive or negative groups.
Another limitation of the study is that it was not possible to
perform periodontal examinations on the healthy controls, since
the samples were already collected and included previously as a
part of another study. However, it is plausible to presume that the
periodontal status in this control group more or less varied, and
consequently this suggests that the differences between patients
and a periodontal healthy control may be even more pronounced
than shown in this study.5. Conclusion
In summary, we conclude that patients with CAD have a
systemic HGF proﬁle reﬂecting a chronic inﬂammatory condition
with a high concentration, but low biological activity of HGF. The
biological activity of HGF is temporarily elevated after dilation of
the stenotic artery, however, only in patients without period-
ontitis. Consequently, administration of biologically active HGF
may be an important research focus of future strategies in the
treatment of patients with CAD.
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